655 Elizabeth Street
Melbourne, VIC 3000
Australia
61 3 9389 1911
https://www.csl.com.au
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 32.065
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Paul F. McKenzie Ph.D. | MD, CEO & Executive Director | 4,11M | N/D | 1966 |
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer | 3,06M | N/D | 1965 |
Mr. Mark Dehring | Head of Investor Relations | N/D | N/D | N/D |
Mr. Gregory Boss B.S., BS(Hons), J.D. | Executive VP of Legal & General Counsel | 1,63M | N/D | 1961 |
Christina Hickie | Senior Manager of Communications | N/D | N/D | N/D |
Ms. Roanne Parry | Chief Human Resources Officer | N/D | N/D | N/D |
Dr. Karen Etchberger | Executive Vice President of Quality & Business Services | 1,54M | N/D | 1958 |
Ms. Jemimah Brennan | Head of Communications - Asia Pacific | N/D | N/D | N/D |
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D. | Senior Vice President of Research | N/D | N/D | 1962 |
Dr. William Mezzanotte M.D., M.P.H. | Executive VP & Head of Research and Development | 2,17M | N/D | 1959 |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
L'ISS Governance QualityScore di CSL Limited al 1 maggio 2024 è 2. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 4; diritti degli azionisti: 1; retribuzione: 4.